jrnls.org logo
Submit

BROWSE ALL JOURNALS

Type 2 letters to search all 19 journals

SEE ALL 19 JOURNALS
Indian Journal of Pharmaceutical Education and ResearchNOW IN
Back

IJPER · Lens · COVID-19 Vaccine Development, Trials and Tribulations

PDF

Review · Volume 54, Issue 3S · pp. s457–s463

COVID-19 Vaccine Development, Trials and Tribulations

Juny Sebastian1, Mandyam Dhati Ravi2, Tegginamat Pramod Kumar3

  1. 1Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education and Research, S S Nagara, Mysuru, Karnataka, INDIA.
  2. 2Department of Pediatrics, JSS Medical College and Hospital, JSS Academy of Higher Education and Research, S S Nagara, Mysuru, INDIA.
  3. 3Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, S S Nagara, Mysuru, Karnataka, INDIA.

Abstract

The coronavirus disease 19 (COVID-19) is a pandemic viral infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Currently, COVID-19 has affected 210 countries and territories around the world. But there is no clinically approved antiviral drug or vaccine against COVID-19. Governments, private manufactures, academic institutions and non-profit organizations are working hard at a breakneck pace to develop a vaccine for COVID-19. However, vaccine development is very lengthy and expensive process, typically takes many years to produce a licensed vaccine. Because of the high failure rates and cost factors, developers generally follow a linear development sequence with multiple pauses for analysis of data. But in view of the COVID-19 pandemic, development steps need to be executed parallel before confirming the outcome of the previous step. In the current review, we summarize the process involved in the COVID-19 vaccine development and its challenges.

Keywords: Candidate Vaccine; Corona Virus; COVID-19 Vaccine; SARS-CoV-2; Vaccine Clinical Trial; Vaccine Development

The full text of this article is available as a PDF. Open the PDF.